Sugi Predict

Sugi Predict / Compounds / SCHEMBL664995

SCHEMBL664995

SCHEMBL664995

CC(C)(C)[Si](C)(C)OCCOc1ccc(C=O)cc1

nearest known ligand 0.50

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.50
▸ SMN1; SMN2 Q16637 3/20 0.50
▸ MAPT P10636 2/20 0.50
▸ HPGD P15428 2/20 0.50
▸ LMNA P02545 2/20 0.50
▸ CYP2A6 P11509 1/20 0.42
▸ MEN1 O00255 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ KDM4E B2RXH2 4/20 0.41
▸ DUT P33316 1/20 0.39
▸ ALDH1A3 P47895 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ FDPS P14324 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ PTPN1 P18031 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17100452 0.92 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2MAPTHPGDLMNA
SCHEMBL14648388 0.84 CHRNA7 (0.49) ALDH1A1SMN1; SMN2MAPTHPGDLMNA
SCHEMBL616129 0.82 MAOA (0.48) SMN1; SMN2MEN1KMT2AL3MBTL1RAB9A
SCHEMBL31115543 0.82 MAOA (0.48) SMN1; SMN2MEN1KMT2AL3MBTL1RAB9A
SCHEMBL5857320 0.80 MEN1 (0.45) ALDH1A1SMN1; SMN2MAPTHPGDLMNA
SCHEMBL15831460 0.80 DRD2 (0.44) ALDH1A1SMN1; SMN2MEN1KMT2ADUT
SCHEMBL30467056 0.80 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2MAPTHPGDLMNA
SCHEMBL20303039 0.80 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2MAPTHPGDLMNA
SCHEMBL377842 0.80 MEN1 (0.36) ALDH1A1SMN1; SMN2MAPTHPGDLMNA
SCHEMBL2356225 0.79 ALDH1A1 (0.41) ALDH1A1SMN1; SMN2MAPTHPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111491623-A Compounds and their use in the treatment of cancer 阿斯利康(瑞典)有限公司 2020-08-04 — — CN disclosed
US-20190194190-A1 Compounds and Their Use in Treating Cancer ASTRAZENECA PHARMACEUTICALS LP 2019-06-27 — — US disclosed
US-20190194190-A1 Compounds and Their Use in Treating Cancer ASTRAZENECA PHARMACEUTICALS LP 2019-06-27 — — US disclosed
US-9896479-B2 Functionalized naphthalene fluorophores Kay M. Brummond (US) 2018-02-20 — — US disclosed
EP-3119760-A1 PIPERIDINE-DIONE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2017-01-25 — — EP disclosed
US-20170001990-A1 PIPERIDINE-DIONE DERIVATIVES GENENTECH, INC. (US) 2017-01-05 — — US disclosed
US-20150297596-A1 ISOXAZOLINES AS THERAPEUTIC AGENTS ABBVIE INC. (US) 2015-10-22 — — US disclosed
US-20150297596-A1 ISOXAZOLINES AS THERAPEUTIC AGENTS ABBVIE INC. (US) 2015-10-22 — — US disclosed
US-20150297596-A1 ISOXAZOLINES AS THERAPEUTIC AGENTS ABBVIE INC. (US) 2015-10-22 — — US disclosed
WO-2015140133-A1 PIPERIDINE-DIONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2015-09-24 — — WO disclosed
US-20040242884-A1 ANTIVIRAL COMPOUNDS PHARMACIA & UPJOHN COMPANY 2004-12-02 — — US disclosed
EP-1472260-A2 THIENO(3,2-B)PYRIDONES AS ANTIVIRAL COMPOUNDS PHARMACIA & UPJOHN COMPANY (US) 2004-11-03 — — EP disclosed
WO-2003059878-A2 THIENO (3, 2-B) PYRIDONES AS ANTIVIRAL COMPOUNDS PHARMACIA & UPJOHN COMPANY (US) 2003-07-24 — — WO disclosed
US-6555570-B2 Growth hormone secretagogous with improved bioavailability NOVO NORDISK A/S (DE) 2003-04-29 — — US disclosed
US-20030055261-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-03-20 — — US disclosed
US-20030040483-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-02-27 — — US disclosed
US-6127391-A A PEPTIDE MIMETIC COMPOUND FOR STIMULATING THE RELEASE OF GROWTH HORMONE FROM THE PITUITARY NOVO NORDISK A/S (DK) 2000-10-03 — — US disclosed
US-5977178-A Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 1999-11-02 — — US disclosed
EP-0869974-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1998-10-14 — — EP disclosed
WO-1997023508-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1997-07-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150297596-A1 ISOXAZOLINES AS THERAPEUTIC AGENTS CYP3A7, CYP11B2, CYP11B1 ALDH1A1 176/4885SMN1; SMN2 3443/4885MAPT 2444/4885
US-20030055261-A1 Compounds with growth hormone releasing properties GHRHR, GHSR, IGFBP1 ALDH1A1 2804/4885SMN1; SMN2 1242/4885MAPT 4183/4885
US-20170001990-A1 PIPERIDINE-DIONE DERIVATIVES DRD4, ADORA1, ADORA3 ALDH1A1 132/4885SMN1; SMN2 1340/4885MAPT 23/4885
US-20040242884-A1 ANTIVIRAL COMPOUNDS ZC3HAV1, IRF3, IFNAR1 ALDH1A1 1593/4885SMN1; SMN2 947/4885MAPT 3255/4885
US-20030040483-A1 Compounds with growth hormone releasing properties GHRHR, GHSR, GRPR ALDH1A1 2542/4885SMN1; SMN2 1369/4885MAPT 4357/4885
US-20190194190-A1 Compounds and Their Use in Treating Cancer F12, CCNY, CCNE1 ALDH1A1 333/4885SMN1; SMN2 1942/4885MAPT 4490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.